Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19.

This analysis describes the prevalence of contraindications to nirmatrelvir/ritonavir among 66 007 patients with coronavirus disease 2019 in a large health care system. A possible contradiction was present in 9830 patients (14.8%), with the prevalence of contraindications increasing with higher acuity of illness.
Competing Interests: Potential conflicts of interest. D.R.B. has conducted clinical trials of outpatient COVID-19 therapies. Otherwise, the authors declare no conflicts of interest related to this work. The authors: no reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.
(© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)